JMD TIDES - Oligonucleotide and Peptide - May 18-21, 2008, Las Vegas, NV
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Q.
Right arrow Articles by Wang, Y. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chen, Q.
Right arrow Articles by Wang, Y. L.
JMD 2007, Vol. 9, No. 2
Copyright © 2007 American Society for Investigative Pathology & Association for Molecular Pathology


Consultations in Molecular Diagnostics

Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders

Qiaofang Chen*, Pin Lu{dagger}, Amy V. Jones{ddagger}, Nicholas C.P. Cross{ddagger}, Richard T. Silver§ and Y. Lynn Wang*

From the Department of Pathology and Laboratory Medicine, * and the Department of Medicine, § Division of Hematology, Weill Medical College of Cornell University, New York, New York; the Immunoregulation Laboratory, {dagger} Hospital of Special Surgery, New York, New York; and the Wessex Regional Genetics Laboratory, {ddagger} University of Southampton, Salisbury District Hospital, Salisbury, United Kingdom

Abstract

An acquired mutation in Janus kinase 2 (JAK2), V617F, has recently been identified in human myeloproliferative disorders. Detection of the mutation is helpful in differential diagnosis, prognosis, and predication of therapeutic response. Because the mutation can be present in a small proportion of granulocytic populations in myeloproliferative disorder patients, a highly sensitive detection method is required. In this study, we systematically optimized the reaction conditions of a published amplification refractory mutation system-polymerase chain reaction research protocol to make it a robust clinical diagnostic test. The modifications led to a clear demonstration of the V617F mutation in a patient who would have been easily missed by the original amplification refractory mutation system-polymerase chain reaction assay. The test detects the V617F mutation not only with a high analytic sensitivity of 0.05 to 0.1% but also with a high diagnostic specificity of 99%. In addition, the assay has the ability to distinguish cases with only mutant alleles from cases with mixed normal and mutant alleles. The assay is fast and easy to perform, and no special equipment other than thermocyclers is required. All these features make the assay readily and broadly applicable in clinical molecular diagnostic laboratories.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society for Investigative Pathology and the Association for Molecular Pathology.